BioSig (BSGM) 10-Q 4 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 04, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		34,619,071
Amendment Flag	false
Entity Central Index Key	1,530,766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 1,035,100	$ 1,547,579
Prepaid expenses	119,111	116,938
Total current assets	1,154,211	1,664,517
Property and equipment, net	19,457	18,716
Deposits	22,477	17,084
Total assets	1,196,145	1,700,317
Current liabilities:
Accounts payable and accrued expenses, including $27,375 and $15,755 to related parties as of December 31, 2017 and 2016, respectively	338,811	473,098
Dividends payable	482,636	447,901
Warrant liability	0	2,358,240
Derivative liability	0	685,922
Total current liabilities	821,447	3,965,161
Convertible Preferred Stock	965,000	985,000
Preferred stock
Common stock, $0.001 par value, authorized 200,000,000 shares, 29,321,204 and 22,588,184 issued and outstanding as of December 31, 2017 and 2016, respectively	30,498	29,321
Additional paid in capital	55,381,386	53,215,635
Commitments and contingencies	115,470	29,985
Accumulated deficit	(56,117,658)	(56,524,786)
Total stockholders’ deficit	(590,302)	(3,249,844)
Total liabilities and stockholders’ deficit	1,196,145	1,700,317
Series D Preferred Stock [Member]
Current liabilities:
Preferred stock	1	$ 1
Series E Preferred Stock [Member]
Current liabilities:
Preferred stock	$ 1

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Accounts payable and accrued expenses, related parties (in Dollars)	$ 7,236	$ 27,375
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	30,497,707	29,321,204
Common stock, shares outstanding	30,497,707	29,321,204
Series C Preferred Stock [Member]
Preferred stock, shares issued	965	985
Preferred stock, shares outstanding	965	985
Preferred stock, liquidation preference (in Dollars)	$ 965,000	$ 985,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series D Preferred Stock [Member]
Preferred stock, liquidation preference (in Dollars)	$ 1,030,500	$ 2,001,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,400	1,400
Preferred Stock, shares issued	687	1,334
Preferred Stock, shares outstanding	687	1,334
Series E Preferred Stock [Member]
Preferred stock, liquidation preference (in Dollars)	$ 1,500,000	$ 0
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred Stock, shares issued	1,000	0
Preferred Stock, shares outstanding	1,000	0

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Research and development	$ 862,420	$ 1,338,604
General and administrative	1,771,796	1,557,341
Depreciation	2,903	3,069
Total operating expenses	2,637,119	2,899,014
Loss from operations	(2,637,119)	(2,899,014)
Other income (expense):
Loss on change in fair value of derivatives	0	(373,611)
Interest income	85	0
Loss before income taxes	(2,637,034)	(3,272,625)
Income taxes (benefit)	0	0
Net loss	(2,637,034)	(3,272,625)
Preferred stock dividend	(305,046)	(23,745)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (2,942,080)	$ (3,296,370)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.09)	$ (0.14)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	29,944,445	23,051,872

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 3 months ended Mar. 31, 2018 - USD ($)	Preferred Stock [Member]Series D Preferred Stock [Member]Settlement of Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]Settlement of Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]	Common Stock [Member]Series D Preferred Stock [Member]Settlement of Preferred Stock [Member]	Common Stock [Member]Series D Preferred Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]Settlement of Preferred Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Series D Preferred Stock [Member]Settlement of Preferred Stock [Member]	Additional Paid-in Capital [Member]Series D Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]Settlement of Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscription [Member]Series D Preferred Stock [Member]Settlement of Preferred Stock [Member]	Common Stock Subscription [Member]Series D Preferred Stock [Member]	Common Stock Subscription [Member]Series C Preferred Stock [Member]Settlement of Preferred Stock [Member]	Common Stock Subscription [Member]Series C Preferred Stock [Member]	Common Stock Subscription [Member]	Retained Earnings [Member]Series D Preferred Stock [Member]Settlement of Preferred Stock [Member]	Retained Earnings [Member]Series D Preferred Stock [Member]	Retained Earnings [Member]Series C Preferred Stock [Member]Settlement of Preferred Stock [Member]	Retained Earnings [Member]Series C Preferred Stock [Member]	Retained Earnings [Member]	Series D Preferred Stock [Member]Settlement of Preferred Stock [Member]	Series C Preferred Stock [Member]Settlement of Preferred Stock [Member]	Series C Preferred Stock [Member]	Total
Balance at Dec. 31, 2017		$ 1							$ 29,321					$ 53,215,635					$ 29,985					$ (56,524,786)				$ (3,249,844)
Balance (in Shares) at Dec. 31, 2017		1,334		0					29,321,204																			29,321,204
Fair value of warrant issued to acquire research and development		$ 0		$ 0					$ 0					0					0					3,044,162				$ 3,044,162
Common stock issued for services		$ 0		$ 0					$ 100					141,900					0					0				142,000
Common stock issued for services (in Shares)		0		0					100,000
Sale of common stock		$ 0		$ 0					$ 200					299,785					(29,985)					0				270,000
Sale of common stock (in Shares)		0		0					200,000
Common stock issued upon conversion of preferred stock and accrued dividends	$ 0	$ 0	$ 0	$ 0	$ 210	$ 647	$ 7	$ 13		$ 261,825	$ (647)	$ 8,269	$ 19,987		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 262,035	$ 8,276	$ 20,000
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)	0	(647)	0	0	209,574	647,000	6,595	13,334
Sale of Series D preferred stock		$ 0		$ 1					$ 0					1,492,968					0					0				1,492,969
Sale of Series D preferred stock (in Shares)		0		1,000					0
Common stock subscription received		$ 0		$ 0					$ 0					0					115,470					0				115,470
Stock based compensation		0		0					0					246,710					0					0				246,710
Preferred Stock dividend		0		0					0					(305,046)					0					0				(305,046)
Net loss		0		0					0					0					0					(2,637,034)				(2,637,034)
Balance at Mar. 31, 2018		$ 1		$ 1					$ 30,498					$ 55,381,386					$ 115,470					$ (56,117,658)				$ (590,302)
Balance (in Shares) at Mar. 31, 2018		687		1,000					30,497,707																			30,497,707

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals)	Mar. 31, 2018$ / shares
Preferred Stock [Member] | Series D Preferred Stock [Member]
Conversion of preferred stock	$ 1.50
Common Stock [Member] | Series D Preferred Stock [Member]
Common stock issued	1.25
Common Stock [Member] | Series C Preferred Stock [Member] | Settlement of Preferred Stock [Member]
Common stock issued	$ 1.25

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,637,034)	$ (3,272,625)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	2,903	3,069
Change in derivative liabilities	0	373,611
Equity based compensation	388,710	560,746
Fair value of issued warrant to acquire research and development	0	543,927
Changes in operating assets and liabilities:
Prepaid expenses	(2,173)	(27,514)
Payment of long term deposit	(5,393)	0
Accounts payable	(134,714)	209,466
Deferred rent payable	427	(521)
Net cash used in operating activities	(2,387,274)	(1,609,841)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(3,644)	(1,620)
Net cash used in investing activity	(3,644)	(1,620)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	270,000	1,799,692
Proceeds from sale of Series E preferred stock	1,492,969	0
Proceeds from common stock subscription	115,470	0
Net cash provided by financing activities	1,878,439	1,799,692
Net increase in cash and cash equivalents	(512,479)	188,231
Cash and cash equivalents, beginning of the period	1,547,579	1,055,895
Cash and cash equivalents, end of the period	1,035,100	1,244,126
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Non cash investing and financing activities:
Accrual of dividend payable charged to additional paid in capital	305,046	23,745
Series C Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	28,276	0
Series D Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	262,035	0
Embedded Derivative Financial Instruments [Member]
Non cash investing and financing activities:
Reclassify derivative liability to equity	$ 3,044,162	$ 0

NOTE 1 - NATURE OF OPERATIONS A

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2018
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed balance sheet as of December 31, 2017 has been derived from audited financial statements. Operating results for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2017 filed with the Company’s Form 10-K/A with the Securities and Exchange Commission on March 26, 2018.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of March 31, 2018, the Company had cash of $1,035,100 and working capital of $332,764. The Company raised approximately $1,500,000 through the sale of Series E preferred stock and warrants and $385,000 through the sale of common stock and warrants during the three months ended March 31, 2018 and approximately $4,675,000 subsequent to March 31, 2018 (See Note 11). During the three months ended March 31, 2018, the Company used net cash in operating activities of $2,387,274. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months. The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at March 31, 2018 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 - SUMMARY OF SIGNIFICANT

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges. At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7). Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420 and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2018 March 31, 2017 Series C convertible preferred stock 643,333 713,333 Series D convertible preferred stock 687,000 - Series E convertible preferred stock 1,000,000 - Options to purchase common stock 8,230,319 8,245,190 Warrants to purchase common stock 12,237,628 10,419,655 Totals 22,798,280 19,378,178 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested. As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as non-current. Registration Rights On February 16, 2018, in connection with the Company’s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered. The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018. Adoption of Accounting Standards In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows: March 31, 2018 December 31, 2017 Computer equipment $ 90,703 $ 87,059 Furniture and fixtures 12,975 12,975 Subtotal 103,678 100,034 Less accumulated depreciation (84,221 ) (81,318 ) Property and equipment, net $ 19,457 $ 18,716 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $2,903 and $3,069 for the three months ended March 31, 2018 and 2017, respectively.

NOTE 5 - ACCOUNTS PAYABLE AND A

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following: March 31, 2018 December 31, 2017 Accrued accounting and legal $ 151,745 $ 93,595 Accrued reimbursements 10,510 2,600 Accrued consulting 12,650 109,059 Accrued research and development expenses 148,932 246,030 Accrued office and other 644 7,912 Deferred rent 997 569 Accrued settlement related to arbitration 13,333 13,333 $ 338,811 $ 473,098

NOTE 6 - SERIES C 9% CONVERTIBL

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	3 Months Ended
	Mar. 31, 2018
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301. In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends. In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends. Series C Preferred Stock issued and outstanding totaled 965 and 985 as of March 31, 2018 and December 31, 2017, respectively. As of March 31, 2018 and December 31, 2017, the Company has accrued $432,660 and $419,283 dividends payable on the Series C Preferred Stock.

NOTE 7 - WARRANT AND DERIVATIVE

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES	3 Months Ended
	Mar. 31, 2018
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES Series C 9% Convertible Preferred Stock and related warrants At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required. There was no established market for the Company’s common stock. As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%. Series D Convertible Preferred Stock and related warrants At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively. The Company valued the reset provisions of the Series D Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%. At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%. On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

NOTE 8 - STOCKHOLDER EQUITY

NOTE 8 - STOCKHOLDER EQUITY	3 Months Ended
	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2018 and December 31, 2017, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock and (2018) 1,000 shares of Series E Preferred Stock. As of March 31, 2018 and December 31, 2017, there were no outstanding shares of Series A and Series B preferred stock. Series C Preferred Stock In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends. In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends. Series D Preferred Stock In January 2018, the Company issued an aggregate of 235,911 shares of its common stock in exchange for 180 shares of the Company’s Series D Preferred Stock and accrued dividends. In February 2018, the Company issued an aggregate of 131,432 shares of its common stock in exchange for 100 shares of the Company’s Series D Preferred Stock and accrued dividends. In March 2018, the Company issued an aggregate of 489,231 shares of its common stock in exchange for 367 shares of the Company’s Series D Preferred Stock and accrued dividends. Series E Preferred Stock On February 16, 2018, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the “Preferred Shares”) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.75 per share (the “Warrants”), in exchange for aggregate consideration of $1,492,969, net of transaction expenses of $7,031 (the “Transaction”). The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type. The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the “ROFR”) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement)) Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering. In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered. The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share. The Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the “Consent”) with the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Holders”). Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction. In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the “Consent Warrants”). The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share. The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. Common stock The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2018 and December 31, 2017, the Company had 30,497,707 and 29,321,204 shares issued and outstanding, respectively. During the three months ended March 31, 2018, the Company issued 100,000 shares of its common stock for services totaling $142,000 ($1.42 per share). During the three months ended March 31, 2018, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 180,000 shares of common stock and 90,000 warrants for aggregate proceeds of $270,000. During the three months ended March 31, 2018, the Company issued 20,000 shares of common stock and 10,000 warrants for a previously received common stock subscription of $29,985.

NOTE 9 - OPTIONS AND WARRANTS

NOTE 9 - OPTIONS AND WARRANTS	3 Months Ended
	Mar. 31, 2018
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 – OPTIONS AND WARRANTS Options On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The following table presents information related to stock options at March 31, 2018: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 3,545,540 7.2 2,483,540 2.01-3.00 4,384,779 3.4 4,384,779 3.01-4.00 300,000 7.0 300,000 8,230,319 5.2 7,168,319 A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2017 8,510,319 $ 2.11 5.2 $ 27,045 Grants 50,000 $ 1.42 10.0 $ - Exercised - Canceled (330,000 ) 1.66 Outstanding at March 31, 2018 8,230,319 $ 2.12 5.2 $ 158,930 Exercisable at March 31, 2018 7,168,319 $ 2.20 4.7 $ 104,305 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.57 as of March 31, 2018, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the three months ended March 31, 2018 and 2017 was estimated using the Black-Scholes pricing model. On February 15, 2018, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.42 per share for a term of ten years with vesting immediately. The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018: Risk-free interest rate 2.65 % Dividend yield 0 % Stock price volatility 94.10 % Expected life 5 years Weighted average grant date fair value $ 1.01 The fair value of all options vesting during the three months ended March 31, 2018 and 2017 of $246,710 and $42,984, respectively, was charged to current period operations. Unrecognized compensation expense of $783,894 and $979,812 at March 31, 2018 and December 31, 2017, respectively, will be expensed in future periods. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 7,615,982 February 2018 to May 2021 $ 1.75 500,000 August 2021 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 12,237,628 On January 5, 2018, the Company issued 100,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on January 5, 2021, in connection with the sale of the Company’s common stock. On February 14, 2018, the Company entered into a consent agreement with the holders of the Company’s Series D Convertible Preferred Stock. Pursuant to the consent, the Series D Holders consented to the Series E Preferred Stock transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the transaction. In consideration for their entry into the consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of common stock. The consent warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share. The warrants contain certain anti-dilutive provisions (see Note 8). On February 16, 2018, the Company issued an aggregate of 500,000 warrants to purchase the Company’s common stock at $1.75 per share, expiring on August 16, 2021, in connection with the sale of the Company’s Series E preferred stock. The warrants contain certain anti-dilutive provisions (see Note 8). A summary of the warrant activity for the three months ended March 31, 2018 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 Grants 700,000 $ 1.68 3.0 - Exercised - Expired (1,251,458 ) $ 1.50 - - Outstanding at March 31, 2018 12,237,628 $ 1.85 1.7 $ 1,134,548 Vested and expected to vest at March 31, 2018 12,237,628 $ 1.85 1.7 $ 1,134,548 Exercisable at March 31, 2018 12,237,628 $ 1.85 1.7 $ 1,134,548

NOTE 10 - FAIR VALUE MEASUREMEN

NOTE 10 - FAIR VALUE MEASUREMENT	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 10 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of March 31, 2018 and December 31, 2017, the Company did not have any items that would be classified as level 1 or 2 disclosures. As of March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges. The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of March 31, 2018: Warrant Liability Derivative Balance, December 31, 2017 $ 2,358,240 $ 685,922 Total (gains) losses Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018 (2,358,240 ) (685,922 ) Balance, March 31, 2018 $ - $ -

NOTE 11 - SUBSEQUENT EVENTS

NOTE 11 - SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11 – SUBSEQUENT EVENTS In April 2018, the Company issued an aggregate of 577,339 shares of its common stock in exchange for 454 shares of the Company’s Series D Preferred Stock and accrued dividends. In April 2018, the Company issued an aggregate of 351,021 shares of its common stock in exchange for 370 shares of the Company’s Series C Preferred Stock and accrued dividends. On April 30, 2018 the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 3,193,004 shares of the Company’s common stock and warrants to purchase an aggregate of 1,596,506 shares of the Company’s common stock, at an exercise price of $1.75 per share, in exchange for aggregate consideration of $4,789,502, net of transaction expenses of approximately $1,000 (the “April 2018 private placement”), of which $115,470 was received as common stock subscriptions as of March 31, 2018. In connection with the April 2018 private placement, the Company issued additional warrants to purchase an aggregate of 83,334 shares of the Company’s common stock, at an exercise price of $1.50 per share to the Series E holders. In addition, 500,000 warrants to purchase the Company’s common stock at an exercise price of $1.75 per share previously issued to the Series E holders were reset to an exercise price of $1.50 per share.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges. At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420 and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2018 March 31, 2017 Series C convertible preferred stock 643,333 713,333 Series D convertible preferred stock 687,000 - Series E convertible preferred stock 1,000,000 - Options to purchase common stock 8,230,319 8,245,190 Warrants to purchase common stock 12,237,628 10,419,655 Totals 22,798,280 19,378,178
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested. As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as non-current.
Registration Rights Policy [Policy Text Block]	Registration Rights On February 16, 2018, in connection with the Company’s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered. The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018.
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Accounting Standards In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.

NOTE 3 - SUMMARY OF SIGNIFICA20

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2018 March 31, 2017 Series C convertible preferred stock 643,333 713,333 Series D convertible preferred stock 687,000 - Series E convertible preferred stock 1,000,000 - Options to purchase common stock 8,230,319 8,245,190 Warrants to purchase common stock 12,237,628 10,419,655 Totals 22,798,280 19,378,178

NOTE 4 - PROPERTY AND EQUIPME21

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows March 31, 2018 December 31, 2017 Computer equipment $ 90,703 $ 87,059 Furniture and fixtures 12,975 12,975 Subtotal 103,678 100,034 Less accumulated depreciation (84,221 ) (81,318 ) Property and equipment, net $ 19,457 $ 18,716

NOTE 5 - ACCOUNTS PAYABLE AND22

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following: March 31, 2018 December 31, 2017 Accrued accounting and legal $ 151,745 $ 93,595 Accrued reimbursements 10,510 2,600 Accrued consulting 12,650 109,059 Accrued research and development expenses 148,932 246,030 Accrued office and other 644 7,912 Deferred rent 997 569 Accrued settlement related to arbitration 13,333 13,333 $ 338,811 $ 473,098

NOTE 9 - OPTIONS AND WARRANTS (

NOTE 9 - OPTIONS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at March 31, 2018: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 3,545,540 7.2 2,483,540 2.01-3.00 4,384,779 3.4 4,384,779 3.01-4.00 300,000 7.0 300,000 8,230,319 5.2 7,168,319
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2017 8,510,319 $ 2.11 5.2 $ 27,045 Grants 50,000 $ 1.42 10.0 $ - Exercised - Canceled (330,000 ) 1.66 Outstanding at March 31, 2018 8,230,319 $ 2.12 5.2 $ 158,930 Exercisable at March 31, 2018 7,168,319 $ 2.20 4.7 $ 104,305
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018: Risk-free interest rate 2.65 % Dividend yield 0 % Stock price volatility 94.10 % Expected life 5 years Weighted average grant date fair value $ 1.01
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 7,615,982 February 2018 to May 2021 $ 1.75 500,000 August 2021 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 12,237,628
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the three months ended March 31, 2018 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 Grants 700,000 $ 1.68 3.0 - Exercised - Expired (1,251,458 ) $ 1.50 - - Outstanding at March 31, 2018 12,237,628 $ 1.85 1.7 $ 1,134,548 Vested and expected to vest at March 31, 2018 12,237,628 $ 1.85 1.7 $ 1,134,548 Exercisable at March 31, 2018 12,237,628 $ 1.85 1.7 $ 1,134,548

NOTE 10 - FAIR VALUE MEASUREM24

NOTE 10 - FAIR VALUE MEASUREMENT (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of March 31, 2018: Warrant Liability Derivative Balance, December 31, 2017 $ 2,358,240 $ 685,922 Total (gains) losses Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018 (2,358,240 ) (685,922 ) Balance, March 31, 2018 $ - $ -

NOTE 2 - GOING CONCERN AND MA25

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	Feb. 16, 2018	May 03, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Cash and Cash Equivalents, at Carrying Value			$ 1,035,100	$ 1,244,126	$ 1,547,579	$ 1,055,895
Working Capital (Deficit)			(332,764)
Net Cash Provided by (Used in) Operating Activities			(2,387,274)	$ (1,609,841)
Series E Preferred Stock [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants	$ 1,492,969		1,500,000
Common Stock and Warrant [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance or Sale of Equity			$ 385,000
Subsequent Event [Member] | Series C and D Preferred Stock [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance or Sale of Equity		$ 4,675,000

NOTE 3 - SUMMARY OF SIGNIFICA26

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Jan. 01, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Accounting Policies [Abstract]
Research and Development Expense		$ 862,420	$ 1,338,604
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		8,230,319		8,510,319
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		7,168,319		7,347,486
Registration Payment Arrangement, Accrual Carrying Value		$ 0
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity	$ 3,044,162

NOTE 3 - SUMMARY OF SIGNIFICA27

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	22,798,280	19,378,178
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	643,333	713,333
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	687,000	0
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,000,000	0
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	8,230,319	8,245,190
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	12,237,628	10,419,655

NOTE 4 - PROPERTY AND EQUIPME28

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 2,903	$ 3,069
Minimum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE 4 - PROPERTY AND EQUIPME29

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 103,678	$ 100,034
Less accumulated depreciation	(84,221)	(81,318)
Property and equipment, net	19,457	18,716
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	90,703	87,059
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 12,975	$ 12,975

NOTE 5 - ACCOUNTS PAYABLE AND30

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 151,745	$ 93,595
Accrued reimbursements	10,510	2,600
Accrued consulting	12,650	109,059
Accrued research and development expenses	148,932	246,030
Accrued office and other	644	7,912
Deferred rent	997	569
Accrued settlement related to arbitration	13,333	13,333
	$ 338,811	$ 473,098

NOTE 6 - SERIES C 9% CONVERTI31

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Jan. 09, 2013	Mar. 31, 2018	Feb. 28, 2018	Mar. 31, 2018	Dec. 31, 2017
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted				700,000
Warrant, Description of Warrant	after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.
Class of Warrant or Right, Outstanding		12,237,628		12,237,628	12,789,086
Conversion of Stock, Shares Issued		10,010	9,919
Warrants at $2.61 [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted	1,330,627
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 2.61
Warrants, Term of Warrants	5 years
Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized	4,200
Preferred Stock, Liquidation Preference, Value (in Dollars)	$ 1,000
Preferred Stock, Dividend Rate, Percentage	9.00%
Temporary Equity, Par Value (in Dollars)	$ 1,000
Preferred Stock, Dividend Payment Terms	payable quarterly
Preferred Stock, Voting Rights	The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description	The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.
Conversion of Stock, Shares Issued		10,010	9,919
Conversion of Stock, Shares Converted		10	10
Temporary Equity, Shares Outstanding		965		965	985
Temporary Equity, Shares Issued		965		965	985
Dividends Payable (in Dollars)		$ 432,660		$ 432,660	$ 419,283
Full-Ratchet Anti-Dilution Protection Provision [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50
Class of Warrant or Right, Outstanding	2,315,301

NOTE 7 - WARRANT AND DERIVATI32

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)	Jan. 01, 2018	Nov. 03, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2015	Dec. 31, 2017
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)		$ 397,162	$ 0		$ 1,242,590	$ 685,922
Derivative Liability, Current (in Dollars)		$ 652,054	0		$ 4,097,444	$ 2,358,240
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)	$ 3,044,162
Embedded Derivative Financial Instruments [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate		1.74%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate		0.00%			0.00%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate		130.00%			141.00%	131.00%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term						0 years
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)			$ 3,044,162	$ 0
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate					0.56%	1.39%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term						1 year 156 days
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate					0.89%	1.89%
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term						3 years 131 days

NOTE 8 - STOCKHOLDER EQUITY (De

NOTE 8 - STOCKHOLDER EQUITY (Details) - USD ($)	Feb. 16, 2018	Feb. 14, 2018	Mar. 31, 2018	Feb. 28, 2018	Jan. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized			1,000,000			1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)			$ 0.001			$ 0.001	$ 0.001
Conversion of Stock, Shares Issued			10,010	9,919
Class of Warrant or Rights, Granted						700,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)			$ 0.001			$ 0.001	$ 0.001
Common Stock, Shares Authorized			200,000,000			200,000,000	200,000,000
Common Stock, Shares, Outstanding			30,497,707			30,497,707	29,321,204
Common Stock, Shares, Issued			30,497,707			30,497,707	29,321,204
Stock Issued During Period, Value, Issued for Services (in Dollars)						$ 142,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)			$ 29,985			$ 29,985
Series A Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized			200			200	200
Series B Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized			600			600	600
Series C Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized			4,200			4,200	4,200
Conversion of Stock, Shares Issued			10,010	9,919
Conversion of Stock, Shares Converted			10	10
Series D Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized			1,400			1,400	1,400
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)			$ 0.001			$ 0.001	$ 0.001
Conversion of Stock, Shares Issued			489,231	131,432	235,911
Conversion of Stock, Shares Converted			367	100	180
Series E Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized			1,000			1,000	1,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.001		$ 0.001			$ 0.001	$ 0.001
Stock Issued During Period, Shares, New Issues	1,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)	$ 1,492,969					$ 1,500,000
Payments of Stock Issuance Costs (in Dollars)	$ 7,031
Sale of Warrants in Connection With Series E Preferred Stock[Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Granted	500,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.75
Consent Agreement, Series D Holders [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Granted	100,000	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50	$ 1.50
Services Provided [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services						100,000
Stock Issued During Period, Value, Issued for Services (in Dollars)						$ 142,000
Shares Issued, Price Per Share (in Dollars per share)			$ 1.42			$ 1.42
Securities Purchase Agreements [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						180,000
Class of Warrant or Rights, Granted						90,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)						$ 270,000
Common Stock Subscription [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						20,000
Class of Warrant or Rights, Granted						10,000

NOTE 9 - OPTIONS AND WARRANTS34

NOTE 9 - OPTIONS AND WARRANTS (Details) - USD ($)	Feb. 16, 2018	Feb. 15, 2018	Feb. 14, 2018	Jan. 05, 2018	Feb. 08, 2017	Oct. 19, 2012	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							50,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vesting immediately
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$ 42,984
Class of Warrant or Rights, Granted							700,000
Warrants at $1.50 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted				100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.50			$ 1.50
Warrant, Expriation Date				Jan. 5, 2021
Warrants at $1.75 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							1.75
Series E Preferred Stock [Member] | Warrants at $1.75 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted	500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.75
Consent Agreement, Series D Holders [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted	100,000		100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50		$ 1.50
Options at $1.42 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price		$ 1.42
2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						15,186,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award						the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Share Price							$ 1.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value							$ 246,710
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 783,894		$ 979,812
2012 Equity Incentive Plan [Member] | Maximum [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						10 years

NOTE 9 - OPTIONS AND WARRANTS35

NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	8,230,319	8,510,319
Options Outstanding, Weighted Average Remaining Life	5 years 73 days	5 years 73 days
Options Exercisable, Number of Options	7,168,319
Options at $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 2
Options Outstanding, Number of Options	3,545,540
Options Outstanding, Weighted Average Remaining Life	7 years 73 days
Options Exercisable, Number of Options	2,483,540
Options at $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 3
Options Outstanding, Number of Options	4,384,779
Options Outstanding, Weighted Average Remaining Life	3 years 146 days
Options Exercisable, Number of Options	4,384,779
Options at $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 3.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 4
Options Outstanding, Number of Options	300,000
Options Outstanding, Weighted Average Remaining Life	7 years
Options Exercisable, Number of Options	300,000

NOTE 9 - OPTIONS AND WARRANTS36

NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	8,230,319	8,510,319
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 2.12	$ 2.11
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 73 days	5 years 73 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$ 158,930	$ 27,045
Options Exercisable, Shares	7,168,319	7,347,486
Options Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 2.20
Options Exercisable, Weighted-Average Remaining Contractual Term	4 years 255 days
Options Exercisable, Aggregate Intrinsic Value (in Dollars)	$ 104,305
Options Granted, Shares	50,000
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 1.42
Options Granted, Weighted-Average Remaining Contractual Term	10 years
Options Exercised, Shares	0
Options Canceled, Shares	(330,000)
Options Canceled, Weighted-Average Exercise Price (in Dollars per share)	$ 1.66

NOTE 9 - OPTIONS AND WARRANTS37

NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	3 Months Ended
	Mar. 31, 2018$ / shares
Minimum [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	2.65%
Dividend yield	0.00%
Stock price volatility	94.10%
Weighted average grant date fair value (in Dollars per share)	$ 1.01
Maximum [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Expected life	5 years

NOTE 9 - OPTIONS AND WARRANTS38

NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	3 Months Ended
	Mar. 31, 2018	Jan. 05, 2018	Dec. 31, 2017
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Number of Warrants Outstanding	12,237,628		12,789,086
Warrants at $0.001 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 0.001
Number of Warrants Outstanding	383,320
Expiration Date, Warrants	January 2,020
Warrants at $1.50 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.50	$ 1.50
Number of Warrants Outstanding	7,615,982
Expiration Date, Warrants	February 2018 to May 2021
Warrants at $1.75 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.75
Number of Warrants Outstanding	500,000
Expiration Date, Warrants	August 2,021
Warrants at $1.84 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.84
Number of Warrants Outstanding	35,076
Expiration Date, Warrants	January 2,020
Warrants at $1.95 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.95
Number of Warrants Outstanding	1,689,026
Expiration Date, Warrants	October 2018 to September 2019
Warrants at $2.00 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2
Number of Warrants Outstanding	100,000
Expiration Date, Warrants	August 2,018
Warrants at $2.02 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.02
Number of Warrants Outstanding	30,755
Expiration Date, Warrants	January 2,020
Warrants at $2.50 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.50
Number of Warrants Outstanding	100,000
Expiration Date, Warrants	August 2,018
Warrants at $2.75 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.75
Number of Warrants Outstanding	228,720
Expiration Date, Warrants	August 2019 to September 2019
Warrants at $3.67 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.67
Number of Warrants Outstanding	214,193
Expiration Date, Warrants	December 2018 to January 2019
Warrants at $3.75 [Member]
NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.75
Number of Warrants Outstanding	1,340,556
Expiration Date, Warrants	April 2019 to March 2020

NOTE 9 - OPTIONS AND WARRANTS39

NOTE 9 - OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	12,237,628	12,789,086
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 1.85	$ 1.82
Warrants Outstanding, Weighted-Average Remaining Contractual Term	1 year 255 days	1 year 255 days
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars)	$ 1,134,548	$ 551,636
Warrants Vested and expected to vest, Shares	12,237,628
Warrants Vested and expected to vest, Weighted-Average Exercise Price (in Dollars per share)	$ 1.85
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term	1 year 255 days
Warrants Vested and expected to vest, Aggregate Intrinsic Value (in Dollars)	$ 1,134,548
Warrants Exercisable, Shares	12,237,628
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 1.85
Warrants Exercisable, Weighted-Average Remaining Contractual Term	1 year 255 days
Warrants Exercisable, Aggregate Intrinsic Value (in Dollars)	$ 1,134,548
Warrants Granted, Shares	700,000
Warrants Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 1.68
Warrants Granted, Weighted-Average Remaining Contractual Term	3 years
Warrants Exercised, Shares	0
Warrants Canceled, Shares	(1,251,458)
Warrants Canceled, Weighted-Average Exercise Price (in Dollars per share)	$ 1.50

NOTE 10 - FAIR VALUE MEASUREM40

NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	3 Months Ended
	Mar. 31, 2018USD ($)
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 2,358,240
Transfers out	(2,358,240)
Balance	0
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	685,922
Transfers out	(685,922)
Balance	$ 0

NOTE 11 - SUBSEQUENT EVENTS (De

NOTE 11 - SUBSEQUENT EVENTS (Details) - USD ($)	Apr. 30, 2018	Feb. 16, 2018	Apr. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Jan. 31, 2018	Mar. 31, 2018
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued				10,010	9,919
Class of Warrant or Rights, Granted							700,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)				$ 29,985			$ 29,985
April 2018 Private Placement [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)				$ 115,470			115,470
April 2018 Private Placement [Member] | Subsequent Event [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	3,193,004
Class of Warrant or Rights, Granted	1,596,506
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.75		$ 1.75
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)	$ 4,789,502
Payments of Stock Issuance Costs (in Dollars)	$ 1,000
Series D Preferred Stock [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued				489,231	131,432	235,911
Conversion of Stock, Shares Converted				367	100	180
Series D Preferred Stock [Member] | Subsequent Event [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued			577,339
Conversion of Stock, Shares Converted			454
Series C Preferred Stock [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued				10,010	9,919
Conversion of Stock, Shares Converted				10	10
Series C Preferred Stock [Member] | Subsequent Event [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued			351,021
Conversion of Stock, Shares Converted			370
Series E Preferred Stock [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		1,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)		$ 1,492,969					$ 1,500,000
Payments of Stock Issuance Costs (in Dollars)		$ 7,031
Series E Preferred Stock [Member] | April 2018 Private Placement [Member] | Subsequent Event [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted			83,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50		$ 1.50